Syndax

#HappeningSoon: Join us for a fireside chat during the Barclays 28th Annual Global Healthcare Conference tomorrow, March 12. At 11:00 a.m. ET, members of Syndax leadership will take the stage and highlight how we are continuing to deliver on our mission in service of patients. Access the dial-in details below: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

#MarkYourCalendars: Tomorrow, members of Syndax leadership will host a fireside chat during the Leerink Global Healthcare Conference 2026. Join our webcast at 10:00 a.m. ET to learn how we are reimagining cancer care: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

Last week, the Syndax team joined one another for our 2026 Spring Commercial & Medical Meeting, which centered on the importance of #NOW. NOW is grounded in where we’ve been and where we are as a Company, with an eye toward where we’re headed together. In addition to hearing from Syndax leadership and our cross-functional colleagues, we had the privilege of welcoming #AML survivor Larry, who shared his inspiring story of grit and gratitude. We concluded the meeting with HCP-supported workshops as well as a Commercial and Medical awards dinner, which recognized the incredible contributions across our team. Thank you to our presenters, colleagues and special guests who demonstrated how what we do NOW can have a transformative impact. #WeFlyHigherTogether

#RareDiseaseDay, a global call to action to generate change for the 300 million patients worldwide living with a rare disease, is today. In 1983, the #OrphanDrugAct was passed and brought more resources toward the research, development, and distribution of #RareDisease therapeutics. More than four decades later, we join the chorus of voices celebrating the continued progress and hope within the rare disease community. Learn more: rarediseaseday.us #PassionforPatients #ShowYourStripes

#ICYMI: Join members of Syndax leadership for a fireside chat on Monday, March 2 at p.m. ET during the TD Cowen 46thAnnual Health Care Conference. Learn more about our dedication to advancing innovative cancer therapies by joining the webcast below: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

#NewsAlert: Today, we reported our fourth quarter and full year 2025 financial results and provided a business update. We solidified our leadership position and proved the strength of Syndax’s R&D and commercial capabilities in 2025, achieving our third FDA approval and successfully launching two first-in-class medicines. Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) have made an impact for thousands of patients and generated over $170 million in revenue to Syndax in 2025, advancing the company towards profitability. With strong momentum and multiple growth drivers for both products, Syndax is well positioned for continued growth in 2026 and beyond. Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET: ir.syndax.com/news-releases/… A live replay will be available after the call for a limited time.

#MarkYourCalendars: Join us for a conference call and webcast on Thursday, February 26 at 4:30 p.m. ET to hear the Syndax team discuss our fourth quarter and full year 2025 financial results and provide a business update. Click the link below for more details: ir.syndax.com/news-releases/… A live replay will be available after the call.

This World #GVHDDay, we show our solidarity with the graft-versus-host disease (#GVHD) community and share our commitment to changing the treatment paradigm for patients. Today, we shine a light on chronic GVHD, the most common long-term complication of allogeneic hematopoietic stem cell transplant. #DYK chronic GVHD affects up to 50% of all transplant recipients? Hear from patient advocate Michael, who was diagnosed with chronic GVHD after achieving remission from a rare, aggressive form of lymphoma and undergoing a bone marrow transplant. #GVHDAlliance

#HappeningSoon: Tomorrow, members of Syndax leadership will take the stage during the 2026 Guggenheim Emerging Outlook: Biotech Summit for a fireside chat. Join our webcast at 12:30 p.m. ET / 9:30 a.m. PT to learn how we are reimagining cancer care: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

Today marks #WorldCancerDay, an international day dedicated to raising awareness of cancer and encouraging its prevention, detection and treatment. Hear from Samantha Nier, Network Director at @AcuteLeuk (ALAN), who shares why she became a patient advocate and how everyone can contribute to ensuring people remain at the center of cancer care. #UnitedByUnique

#NewsAlert: Today, we announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of our presentation at the 44th Annual J.P. Morgan Healthcare conference. 2025 was a transformational year for Syndax as we secured our third FDA approval and successfully executed the launches of Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), proving our ability to deliver innovative therapies for patients and advancing the company towards profitability. With strong momentum and further acceleration of growth going into 2026, we look forward to continuing to build Revuforj and Niktimvo into industry leading franchises and advancing our clinical development programs designed to expand our patient impact and unlock the multi-billion-dollar potential of both medicines. Join the webcast at 3:00 p.m. PT/6:00 p.m. ET to learn more: ir.syndax.com/news-releases/… A live replay will be available for a limited time.

#ICYMI: On Monday, January 12, Chief Executive Officer Michael Metzger will present at the 44th Annual J.P. Morgan Healthcare Conference. Join the webcast at 3:00 p.m. PT/6:00 p.m. ET to learn how we are driving sales growth and unlocking the full potential of our pipeline: ir.syndax.com/events/event-d… A live replay will be available for a limited time.

#NewsAlert: Today, we announced a collaboration with World Orphan Drug Alliance (WODA) to expand access to Revuforj® (revumenib) through a Managed Access Program. In addition to providing a pathway for patients to access Revuforj in regions where it would otherwise be inaccessible, this program will also allow more physicians to gain valuable firsthand experience with the medicine. Learn more by accessing the press release below: ir.syndax.com/news-releases/… #PassionforPatients

At Syndax, patients are at the center of all that we do. We’re proud to partner with @Momcology, a national community-based advocacy and support organization founded in 2011 by mothers of children with cancer. Hear from Kim Buff, Founder and Executive Director of Momcology®, who shares how Momcology’s program, “Connections: Pediatric Cancer Caregiver Support,” provides integral support to patient families and caregivers navigating a pediatric cancer diagnosis. #PassionforPatients

We’re thrilled to announce that Revuforj® (revumenib) has won the “Best New Drug” award during @Citeline’s 2025 #ScripAwards! We’d like to extend our heartfelt gratitude to the Syndax employees, collaborators, and patients who made this achievement possible. Learn more below: ir.syndax.com/news-releases/… #WeFlyHigherTogether

That’s a wrap! We’re honored to have participated in @ASH_hematology’s #ASH25, where we had the privilege of joining other industry innovators who share our aspiration to reimagine cancer care. Learn more: syndax.com #HemOnc #Leukemia

#NewsAlert: Throughout #ASH25, we’ve presented compelling data across our Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) programs. Today, we’re highlighting key Revuforj presentations spanning the treatment continuum. View the press release and tune in to our upcoming investor event at a.m. ET / a.m. PT to learn more: ir.syndax.com/news-releases/… A live replay will be available for a limited time.